Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Amends License Agreement with University of Utah, Yale

NEW YORK, April 29 (GenomeWeb News) - Genaissance Pharmaceuticals announced today that it has signed an amendment to its license agreement with the University of Utah and Yale University relating to cardiac ion channel genes associated with sudden cardiac death syndromes.


The amendment will simplify royalty payments for various genetic tests, including those for cardiac ion channel mutations, the company said. In addition, it will extend Genaissance's licensing rights to the patent estate.


Genaissance originally acquired the license agreement in May 2003 with the acquisition of most of the assets of DNA Sciences, whose IP portfolio included patents developed at Utah and Yale for diagnosing Long QT, Brugada and related syndromes associated with the cardiac ion channel genes.


The company said it expects to launch its test for cardiac ion channel mutations in May.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.